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Background Sows in breeding herds are often mass vaccinated against porcine reproductive 
and respiratory syndrome (PRRS) every few months using modified live vaccines (MLV). Field 
veterinarians repeatedly report that multiple vaccinated sows test negative in ELISA. Obviously, 
this creates uncertainty when assessing the compliance of vaccination and the status of sows. 
Methods In the present study, four commercial ELISAs were used to assess the serological 
PRRS status in gilts and sows of three farms that were PRRS MLV vaccinated every four 
months. Animals were tested before vaccination (BV) and postvaccination (PV). Total and 
neutralising antibodies and cell-mediated responses were also measured in animals that yielded 
negative results in all ELISAs. 
Results The proportion of seronegative animals BV varied depending on the farm and the ELISA 
used. When samples were analysed using only one ELISA, a substantial number of negative 
results obtained BV remained as negative afterwards. Five animals were negative BV and PV 
with all the examined ELISAs. Those animals also yielded negative results in all the other 
immunological assays. 
Conclusion Our findings suggest that the use of ELISA for monitoring multiple PRRS MLV 
vaccinated sows is very limited due to the variability of the humoral responses and the moderate 
agreement between tests. 
 
Introduction 
Since the emergence of the disease in the middle of the 1980s, porcine reproductive and 
respiratory syndrome (PRRS) has been considered one of the most challenging and costly 
diseases for the pig industry.1 The main tools for controlling PRRS are vaccination, management 
of the pig flow and biosecurity measures, as well as the monitoring of the herd either 
serologically or by PCR.2 3 Both inactivated and modified live vaccines (MLV) against PRRS 
virus (PRRSV) are commercially available, with MLV being preferable for the primary 
immunisation.4 Current vaccines induce only partial immunity against the heterologous 
challenge,5–7 but they are effective in reducing the frequency of abortions, stillbirths and other 
reproductive disorders related to PRRSV infection in sows.8 One of the most common PRRSV 
vaccination protocols in breeding herds is based on the application of a blanket vaccination 
approach with recall MLV doses every 3–4 months. In principle, compliance to vaccination or 
simple monitoring of the breeding herd could be achieved by testing sows using an ELISA assay, 
since all vaccinated or infected animals should have tested positive beforehand. Nevertheless, 
swine practitioners often report that some multiply MLV-vaccinated sows give negative results in 
ELISA. This creates uncertainty about the real status of the sows, as well as the performance of 
the ELISAs. The aim of the present study was to assess the presence of PRRSV ELISA-negative 
sows in multiply vaccinated herds and to examine the possible causes of that phenomenon. Four 
different commercial ELISAs were used to determine the serological status of gilts and sows 
before vaccination (BV) and postvaccination (PV). When animals yielded negative results in all 
the ELISAs BV and PV, total and neutralising antibodies, as well as the cell-mediated response 
against PRRSV, were also analysed to evaluate the immune status of the seronegative sows. 
 
 
Materials and methods 
Farms  
The study consisted of three farrow-to-finish farms (designated as F1, F2 and F3), each one 
housing around 300 breeding sows. In F1 and F2, female breeders were Landrace x Largewhite 
x Meishan breedcrosses, while in F3 were Landrace x Largewhite. Semen from Pietrian males 
were used in F1 and F3 and from Duroc ones in F2. In all those farms, the veterinary services 
reported that a high proportion of sows usually tested negative in ELISA (IDEXX PRRS X3; Idexx 
Laboratories, Westbrook, Maine, USA), in spite of being multiply vaccinated with a PRRS MLV. 
In all three farms, the immunisation scheme against PRRSV included the acclimatisation of gilts 
by exposure to the wild-type PRRSV1 present in the farm, with further recall immunisation of 
sows. This was achieved by means of blanket vaccination with a PRRSV1 MLV every 4 months 
(three doses per year). 
 
Experimental design  
The initial sampling (at least n=56, gilts and sows) was designed to detect the presence of 
seronegative sows if their frequency was at least 5% of the breeding stock (95% CI). Eventually, 
171 animals were used: F1 (n=59), F2 (n=60); in F3, only 52 animals could be bled. In order to 
account for differences in the proportion of seronegative sows by parity, the total number of 
samples was distributed as much as possible according to the distribution of parities in the sows’ 
stock. After that first bleeding, animals were immediately vaccinated intramuscularly as usual 
using a commercial PRRSV1 MLV (Porcilis PRRS; MSD Animal Health). Twenty-one days PV, 
the same animals were bled again. Animals yielding negative results in ELISA BV and PV (n=5) 
and other randomly chosen ones (n=55) were bled again into heparinised tubes (28 days PV) in 




All sera collected BV and PV were tested for antibodies against PRRSV using four commercial 
indirect ELISAs as follows: E1 (IDEXX PRRS X3 Ab ELISA), E2 (Pigtype PRRSV Ab; Qiagen, 
Leipzig, Germany), E3 (Ingezim PRRS universal; Inmunologia y Genetica Aplicada SA, Madrid, 
Spain) and E4 (Civtest suis PRRS E/S; Laboratorios Hipra, Amer, Spain). According to the 
manufacturers, all tests are developed to detect IgG antibodies against PRRSV. E1, E2 and E3 
are based on the nucleocapsid as antigen, whereas E4 is coated with nucleocapsid and a 
glycoprotein-rich extract obtained by solubilising whole PRRSV particles. All tests were 
performed according to the manufacturer’s instructions. 
For E1, E2 and E3, results were expressed as a ratio of the optical density (OD) of a given 
sample over the OD of the positive control provided (sample-to-positive (S/P) ratio), whereas a 
relative indexxlOO (IRPC) using the formula described in the manufacturer’s instructions was 
calculated for E4. The positive S/P threshold value was ^.4 for E1 and E2; cut-off was 0.15xOD 
of positive control for E2 and IRPC greater than 20 for E4. In order to minimise the biases, all 
samples from a given farm were tested using the same batch of a given ELISA kit. All samples 
yielding negative or doubtful results in a given ELISA were retested to discard any potential error 
attributable to the laboratory processing. 
For those animals that yielded negative PRRS ELISA results BV and PV, total antibodies 
against Aujeszky’s disease virus (ADV) were also measured using ELISA (Civtest suis ADV; 
Laboratorios Hipra, Amer, Spain). ADV ELISA was performed according to the manufacturer’s 
instructions. Several additional PRRS ELISA positive animals were randomly chosen from each 
farm, and included as controls (n=20). 
Immunofluorescence antibody and viral neutralisation tests  
When an animal was negative by all the ELISAs used BV and PV, postvaccination sera were 
tested in MARC- 145 cell cultures by the immunofluorescence antibody test (IFAT) and by the 
viral neutralisation test (VNT) in order to be able to detect antibodies other than those directed at 
the ELISA antigens (mainly nucleocapsid protein). For the IFAT test, MARC-145 monolayers 
were infected with the vaccine virus for 72 hours and fixed with ethanol at -20°C. After washing 
the plates, samples to be tested were serially diluted from 1:5 to 1:160 and added to the plates 
(45 min 37°C). The plates were then washed and a goat anti-Pig IgG H+L FITC- labelled 
antibody (Abcam, Cambridge, UK) was used to reveal the presence of antibodies against 
PRRSV vaccine strain. Known positive and negative pig sera from other experiments were used 
as controls. Several ELISA-positive and ELISA-negative sera randomly chosen from each farm 
were also included (n=50). The procedure for the VNT was done as previously described9 with 
minor modifications. In this latter case, sera were serially diluted from 1:2 to 1:128, with the sera 
dilutions then being mixed with the PRRSV vaccine strain, and final assessment of the 
neutralisation was made by the addition of an anti-PRRSV antibody (ICH5, Ingenasa, Madrid, 
Spain) and a fluorescein-labelled anti-mouse IgG antibody (Jackson ImmunoResearch 
Laboratories, West Grove, USA). Neutralisation titres of at least 1:4 were considered of biological 
significance. Samples were run in duplicate in both IFAT and VNT assays. Furthermore, known 
positive and negative sera from other studies and several ELISA-positive and ELISA-negative 
serarandomly chosen from each farm were also included. 
 
Interferon-γ enzyme-linked immune absorbent spot (ELISPOT) 
Sows that tested negative in all ELISAs BV and PV were bled again into heparinised tubes (n=5). 
Peripheral blood mononuclear cells (PBMCs) were isolated, and the interferon-γ (IFN-γ) 
ELISPOT for PRRSV was performed as described previously.10 11 The vaccine strain was used 
to stimulate PBMCs at a multiplicity of infection of 0.1. Several ELISA-positive animals were 
randomly chosen from each farm and included as controls (n=55). 
 
Quantitative reverse transcription (qRT)-PCR 
The sera of animals testing negative in all ELISAs BV and PV were analysed by qRT-PCR11 in 
order to assess the persistence of viral replication. Viral RNA was extracted using the BioSprint 
96 One-For-All Vet kit (Qiagen, Leipzig, Germany) and the BioSprint 96 workstation (Qiagen) 
according to the manufacturer’s instructions. A plasmid containing an ORF7 amplicon was used 
as a positive control and for quantification purposes (from 100 to 109 genomic copies/tube). 
Positive and negative controls for the RNA extraction were also included in each analysis. 
Several randomly chosen sera from other ELISA-positive and ELISA-negative animals from all 
three farms were also included for comparative purposes (n=55). 
 
Statistical analyses  
When needed, Excel Software 2013 was used to perform the random selection from the set of 
animals. Descriptive statistics, box-plot representations and inferential statistics, including 
calculation of the correlation coefficient (r2) between S/P values of the ELISAs E1, E2 and E3, 
comparison of the proportions of animals in each category (x2) and the non-parametric Mann-
Whitney U test were performed using Statsdirect V.3.0.167. GraphPad Software was used to 




Distribution of samples according to their S/P or IRPC values is shown in figure 1a-d. In general, 
S/P values were widely scattered within a farm both BV and PV, but the mean S/P or IRPC of the 
population significantly increased PV for all four ELISAs (p<0.05) (figure 1a). However, a more 
detailed examination revealed that the increase was not observed in F3 for any ELISA, or in F1 
for E3, and in any farm for E4 (figure 1b-1d). 
The proportion of seronegative animals BV varied with the farm, as well as with the ELISA kit 
used (table 1). Thus, for F1, seronegative animals BV ranged from 1.7% to 6.8%; in F2, from 
26.7% to 45% and for F3, negative animals accounted from 15.4% to 30.8%, depending on the 
ELISA. The percentage of seronegative animals was reduced PV, except in F1 (5%-10% in F1 
compared with 3.3%-18.0% in F2 and 9.6%-19.2% in F3). Overall, five animals—one in F1 
(parity 7), one in F2 (parity 3) and three in F3 (parities 3, 5, and 6)—were negative BV and PV 
with all the examined ELISAs. 
The animals that yielded positive results BV and PV in a given ELISA were categorised 
according to the magnitude of the changes in the S/P ratios (E1, E2, and E3) or the IRPC (E4) 
BV and PV as follows: (1) the ratio of ELISA values PV and BV was up to 0.5; (2) the ratio 
between the BV and PV values was between 0.5 and 2.0 and (3) the ratio was ≥2.0 (table 2 and 
online supplementary data table 1). For most animals in all farms, the ratio of S/P or IRPC values 
was between 0.5 and 2.0, with no significant differences between ELISAs. This ratio was ≥2.0 
(depending on the ELISA) in only between 13% and 22.7% of the cases. Animals that did not 
seroconvert PV or became negative did not significantly accumulate in older parities.  
As an example, when the distribution of S/P values was examined in detail for one of the most 
used ELISA o detect PRRSV-antibodies (E1), animals that increased the S/P value ≥2 PV had, 
on average, a lower S/P BV than the ones that did not (0.82±0.35 vs 1.35±0.7; p<0.05). 
Nevertheless, some animals with low S/P BV also did not increase PV (figure 2). 
 
Correlation and agreement between tests 
Correlation coefficients between ELISA S/P values for each pair of tests (E1, E2 and E3) are 
shown in table 3 and in online supplementary data figure 1a-1c. Overall, correlation coefficients 
PV were always higher compared with those calculated BV (0.48 vs 0.82 for E1-E2, 0.62 vs 0.80 
for E1-E3 and 0.51 vs 0.71 for E2-E3). To further evaluate the diagnostic agreement between the 
different ELISAs, kappa (k) values were calculated for all samples, and by farm, using the 
Cohen’s Kappa coefficients; table 4 summarises kappa values according to all samples and to 
samples BV and PV, separately. In online supplementary data, tables 2-4 summarise the 
agreements for each farm separately, and online supplementary table 5 shows the distribution of 
positive and negative results according to the ELISAs. Overall, kappa values for all samples 
could be considered from moderate to good, as they ranged from 0.50 (E3-E4) to 0.72 (E2-E3). 
Similar results were obtained when BV and PV periods were individually analysed. Thus, during 
the BV period, the lowest kappa value was obtained for E3-E4 (0.54) and the highest for E2-E3 
(0.73), while during PV period, the lowest corresponded to E3-E4 (0.43) and the highest to E1-E4 
(0.73). 
IFAT, VNT, ELISPOT and additional tests for ELISA-negative animals 
Sera from animals yielding negative results BV and PV in all ELISAs (five animals) were further 
analysed by the IFAT and VNT, yielding negative results in both assays. In contrast, randomly 
selected animals with positive ELISA status were positive for IFAT and VNT. For one animal that 
was positive BV, but became negative in all ELISAs PV, VNT was positive at 1:8. 
The five all-negative sows were then bled again in order to measure the cell-mediated immunity 
against PRRSV using the IFN-γ ELISPOT. All were negative, whereas randomly selected 
animals with different positive ELISA status were positive, with IFN-γ-secreting cell frequencies 
between 25 and 600/106 PBMCs. 
Since the results for the five mentioned animals might suggest a lack of immune response 
against the virus, sera of the pigs were tested by qRT-PCR PV in order to evaluate the possible 
persistence of the vaccine virus. None of them tested positive 21 days PV, and of all the other 
animals, only three tested positive: one in F1 (Cq=36.99, seropositive BV and PV) and two in F3 
(Cq=36.90 and 38.84 of which one was negative BV and positive PV for all ELISAs and the other 
one was positive for three ELISAs BV and positive for two ELISAs PV, respectively). 
During the period of study, animals were also vaccinated against ADV as a part of the routine 
vaccination scheme of the farm. All five animals that yielded negative results in PRRS ELISA BV 
and PV were positive in the ADV ELISA at day 0 and 21 and, as a matter of fact, the mean IRPC 
increased on average from 77 BV to 199.4 PV (cut-off IRPC more than 12.0). 
Discussion 
The origin of the present study were the frequent reports from field veterinarians indicating that 
sows multiple vaccinated with different PRRS MLV became negative in ELISA, a fact that 
created uncertainty about the real immunological status of vaccinated sows, and complicated the 
monitoring of the sow herd. At present, when a considerable proportion of sows test negative in 
ELISA, it is difficult to say if the cause is the lack of compliance of vaccine administration, a 
matter of the ELISA used, a problem related to the immunological response of individuals or to 
other causes. The present study dealt with the investigation of this problem. 
Most commercial PRRS ELISAs use the nucleocapsid protein (N) as the diagnostic antigen in 
indirect ELISA. Antibodies against this protein appear as early as 7-14 days after infection or 
vaccination and are thought to persist for months, and some epitopes in N are shared between 
PRRSV1 and PRRSV2.12-15 However, for PRRSV, it is unclear if there is a classical anamnestic 
humoral response after a re-encounter with the viral antigens,16 17 and thus it is difficult to 
interpret results of the ELISA in multiple vaccinated animals. 
The first point that deserves to be mentioned is the scattering of S/P values obtained with all 
ELISAs, except E3. This can be the result of the different cut-offs of each ELISA, in combination 
with a larger or narrower dynamic range of the ELISA. 
The approach of the present study permitted to observe whether or not individual sows had an 
increase in the S/P ratios or IRPC values PV. Interestingly, animals that had the highest increase 
in the S/P ratios PV had, on average, lower S/P values compared with animals that did not 
increase the S/P. This was not related to parity and, in consequence, with the number of vaccine 
doses received during life. Given that animals were vaccinated every 3-4 months, the interval of 
time between vaccinations would be enough to avoid overlapping with the response to the 
previous vaccination. This would permit an increase in the response if a plateau phase had not 
been reached. In principle, the lack of increase in the S/P can be interpreted as a saturation of 
the specific response, and this seemed to be related more to the individual idiosyncrasy of each 
sow than to the number of times that a sow had been vaccinated, suggesting that the genetic 
background of the pig plays a role. 
Several studies have shown that contact with PRRSV induces antibodies against N protein, 
which for most animals last about 24-32 weeks in either vaccination or infection,14 18 although a 
certain individual variability exists. Certainly, animals negative in ELISA BV could be either truly 
PRRSV-negative pigs or just animals becoming negative for N protein antibodies, but still 
positive to other viral proteins not tested in this study. PV, some sows became positive to all 
ELISAs, others became positive to only some of the tests and finally, five sows remained 
negative to all serological tests. It was evident that the test had an influence on the result. 
Interestingly enough, some previously seropositive animals in a given ELISA became 
negative after a recall immunisation. All of them but one still tested positive in at least two other 
ELISAs and can thus be considered false negative results. The negative one yielded positive 
results in both VNT and ELISPOT, demonstrating that the animal had developed immunity 
against PRRSV. This result suggests that for vaccinated animals testing negative in a given 
ELISA does not necessarily mean the lack of immunity. 
As regards the five animals that remained negative to all tests PV (including IPMA, VNT and 
ELISPOT), compliance was not considered an issue, since vaccination was performed under 
supervision. Interestingly, these animals were healthy and distributed in parities more than 3. 
Therefore, they had been already vaccinated several times before the beginning of the present 
study. In that case, pre-existing immunity could play a role in the immune response in multiply 
vaccinated sows; however, for these particular five sows, neutralising antibodies were not 
detected BV, and therefore the interference of pre-existing immunity seems unlikely for this case. 
These five animals were positive in ELISA against ADV, an antigen against which they were also 
vaccinated, and therefore, the lack of detectable immunity against PRRSV was not due to a 
physiological impossibility (eg, a B immunodeficiency), suggesting that, for some reason, those 
animals did not develop an immune response detectable by the usual means used in PRRS 
testing. Several studies have demonstrated that a single shot of MLV induces a weak and 
delayed response in terms of neutralising antibodies and cell-mediated immunity; however, naive 
animals seroconvert and antibodies can be detected for several months using commercial 
ELISAs.6 14 19 By contrast, other authors have reported that repeated homologous immunisation 
with PRRSV field strains or MLV can induce very limited responses and that the immune 
responses in terms of both humoral and cellular responses cannot be continuously improved by 
this schedule.20-23 Moreover, some authors claimed that repeated MLV immunisation could 
provoke a reduction in the proliferation of effectors and memory T cells,20 and it has even been 
hypothesised that repeated immunisation with MLV may induce a state of anergy.24 However, 
vaccination did not result in a long viraemia in those negative animals, although the strain used is 
considered to replicate poorly in vivo.25 In the present study, just one vaccine was evaluated (one 
of the most sold in Europe). That the use of a different vaccine could have resulted in slightly 
different outcome cannot completely deny; however, the little literature published on this subject 
does not seem to point to such a thing. 
Most gilts in F2 were negative BV, probably indicating a failure in the initial exposure to the 
field strain, since all those gilts were shown to seroconvert in at least one ELISA PV. 
Nevertheless, for a given farm, the number of negative animals, both BV and PV, varied 
depending on the ELISA. Also, for a given ELISA, results varied among farms. As regards farms, 
the causes for this can be diverse including particularities related to management procedures, 
strain(s) that were circulating or idiosyncratic responses related to the genetics. As for the 
ELISAs, the causes could include the particular antigens used in each ELISA (although in 
principle only E4 used an antigen other than the N protein), the potential antigenic diversity of the 
virus and the characteristics of each kit (reagents used, etc). 
As the present study shows, the usefulness of ELISA results is very limited in multiple PRRS-
vaccinated sows, because of the variable humoral response of vaccinated animals and the 
limited agreement between tests. Apart from this, it is worth noting that some multiple vaccinated 
sows may apparently be anergic. This deserves further investigation in order to determine the 
causes and the potential impact of these animals in the epidemiology of the infection. The need 
for improving the monitoring of PRRS-vaccinated herds is becoming increasingly evident. 
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Table 1 Distribution of seronegative animals. Seronegative animals in each farm by parity for four 
commercial ELISAs (E1, E2, E3, and E4) before and after PRRS MLV vaccination (BV and PV, 
respectively), and the number of them that seroconverted (Neg  Pos), remained negative (Neg  Neg) 
or became seronegative (Pos  Neg) after vaccination. 
FARM 1 (n=59) 
Parity Nº of sows 
E1 E2 E3 E4 
BV PV BV PV BV PV BV PV 
0 8 - - - - - - - - 
1 19 - - - - - - - - 
2 8 - - - - - - - - 
3 5 1 1 - - - - 1 1 
4 2 - - - - - - - - 
5 3 - 1 - - - 1 - - 
6 4 - - - - 1 1 - - 
7 8 2 3 1 3 1 4 2 3 
8 2 - - - - - - 1 1 
TOTAL 3 5 1 3 2 6 4 5 
Neg  Pos 
Neg  Neg 













FARM 2 (n=60) 
Parity Nº of sows 
E1 E2 E3 E4 
BV PV BV PV BV PV BV PV 
0 16 12 4 8 2 12 1 10 3 
1 12 2 - 2 - 2 - - 1 
2 11 2 1 - - 3 - - 1 
3 8 3 1 1 - 2 - 1 2 
4 8 5 3 3 - 4 - 3 4 
5 3 1 - - - - - 1 - 
6 1 1 1 1 -- 1 - - - 
7 1 1 1 1 - 1 - 1 1 
TOTAL 27 11 16 2 25 1 16 12 
Neg  Pos 
Neg  Neg 













FARM 3 (n=52) 
Parity Nº of sows 
E1 E2 E3 E4 
BV PV BV PV BV PV BV PV 
3 1 1 1 1 1 1 1 1 1 
4 11 4 2 1 2 2 2 - 1 
5 24 7 3 5 1 6 3 7 2 
6 16 4 4 1 1 1 2 2 1 
TOTAL 16 10 8 5 10 8 10 5 
Neg  Pos 
Neg  Neg 

















Table 2 Percentage of distribution of seropositive animals from all farms. Animals yielded 
positive results before and after PRRS MLV vaccination were classified in three categories 
according to the changes in the S/P ratios (ELISAs E1, E2 and E3) or in the IRPC (ELISA E4): a) 
≤x0.5 in the after vaccination value compared with the before vaccination one, b) animals with a 
change in the ELISAs values between >x0.5 and <x2.0, and c) an increase ≥x2.0 comparing 
before and after vaccination. 
Change of S/P or IRPC 
(after/before vaccination) 
E1 E2 E3 E4 
≤x0.5a 1% 0.7% 0.8% 0.7% 
>x0.5-<x2.0b 86% 76.6% 83% 86% 





Table 3 Correlation coefficients. Correlation coefficients and 95% confidence intervals for the 
comparison of S/P ratios obtained with ELISAs E1, E2 and E3 considering all sera before PRRS 
MLV vaccination (BV) and 21 days post-vaccination, and in total. All coefficients were statistically 
significant (P<0.05). 
 Correlation coefficient r
2 
(95% confidence interval) 































Table 4 Agreements. Kappa values and 95% confidence intervals for the results of samples 
taken before and post-PRRS MLV vaccination (BV and PV, respectively) and in total for the four 
ELISAs used in the study. 
Kappa-value and 95% confidence interval 













E3 - - - 
0.54 
(0.38-0.70) 
E4 - - - - 













E3 - - - 
0.43 
(0.21-0.64) 
E4 - - - - 













E3 - - - 
0.50 
(0.37-0.63) 


























Figs. 1a-1d Boxplots. Boxplots showing S/P (ELISA E1 green, ELISA E2 yellow and ELISA E3 
orange) or IRPC (ELISA E4 blue) values –mean, median, quartiles and range (min, 25, 50, 75, 
max) - considering all samples (Figure 1a) and for each farm (Figure 1b: F1; figure 1c: F2; figure 
1d: F3), before PRRS MLV vaccination (BV) and 21 days post-vaccination (PV).  
Black rhombus: median.  
X: mean.  
Dotted red line: cut-off of the ELISAs. 










Fig. 2 Distribution of S/P ratios for seropositive animals (ELISA E1). According to the 
magnitude of the increases in their S/P ratios animals that yielded positive results using ELISA 
E1 were individually distributed in two categories: increase ≥2 (red bars) or increase <2 (green 
bars) comparing the value obtained after vaccination to the value obtained before vaccination.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
